The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators
Abstract
CONTEXT: Pheochromocytomas and sympathetic paragangliomas are rare neuroendocrine tumors for which no precise histological or molecular markers have been identified to differentiate benign from malignant tumors. OBJECTIVE: The aim was to determine whether primary tumor location and size are associated with malignancy and decreased survival. DESIGN AND SETTING: We performed a retrospective chart review of patients with either pheochromocytoma or sympathetic paraganglioma. PATIENTS: The study group comprised 371 patients. MAIN OUTCOME MEASURES: Overall survival and disease-specific survival were analyzed according to tumor size and location. RESULTS: Sixty percent of patients with sympathetic paragangliomas and 25% of patients with pheochromocytomas had metastatic disease. Metastasis was more commonly associated with primary tumors located in the mediastinum (69%) and the infradiaphragmatic paraaortic area, including the organ of Zuckerkandl (66%). The primary tumor was larger in patients with metastases than in patients without metastatic disease (P < 0.0001). Patients with sympathetic paragangliomas had a shorter overall survival than patients with pheochromocytomas (P < 0.0001); increased tumor size was associated with shorter overall survival (P < 0.001). Patients with sympathetic paragangliomas were twice as likely to die of disease than patients with pheochromocytomas (hazard ratio = 1.93; 95% confidence interval = 1.20-3.12; P = 0.007). As per multivariate analysis, the location of the primary tumor was a stronger predictor of metastases than was the size of the primary tumor. CONCLUSIONS: The size and location of the primary tumor were significant clinical risk factors for metastasis and decreased overall survival duration. These findings delineate the follow-up and treatment for these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893 · cited 3×
“However, a substantial number of patients with metastatic PHEO or PGL ( 50%) do not carry the SDHB germline mutations (19).”
BackgroundMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875 · cited 1×
“Overall 267 (72%) 104 (28%) 371 (100%) Age (yr) 41 (6-83) 41 (5-77) 0.”
SDH5 , a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma
Hao, H.-X., Khalimonchuk, O., Schraders, M., Dephoure, N., Bayley, J.-P., Kunst, H., Devilee, P., Cremers, C. W. R. J., Schiffman, J. D., Bentz, B. G., et al. (2009) · Science · doi:10.1126/science.1175689 · Cited by 702 · cited 3×
“SDHAF2 (PGL syndrome type 2) (11, 12), the SDHA, and”
BackgroundGenetic Testing in Pheochromocytoma or Functional Paraganglioma
Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1484 · Cited by 684
SDHA is a tumor suppressor gene causing paraganglioma
Burnichon, N., Brière, J.-J., Libé, R., Vescovo, L., Rivière, J., Tissier, F., Jouanno, E., Jeunemaitre, X., Bénit, P., Tzagoloff, A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq206 · Cited by 650
Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Gimenez‐Roqueplo, A., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Kien, P. K. V., Corvol, P. L., Plouin, P., & Jeunemaître, X. (2003) · PubMed · Cited by 609
Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes
Benn, D. E., Gimenez-Roqueplo, A.-P., Reilly, J. R., Bertherat, J., Burgess, J., Byth, K., Croxson, M., Dahia, P. L. M., Elston, M., Gimm, O., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1862 · Cited by 570
Control of Enzymatic Synthesis of Adrenaline in the Adrenal Medulla by Adrenal Cortical Steroids
Wurtman, R. J., & Axelrod, J. (1966) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)96620-2 · Cited by 550
Clinical Experience Over 48 Years With Pheochromocytoma
Goldstein, R. E., O’Neill, J. A., Holcomb, G. W., Morgan, W. M., Neblett, W. W., Oates, J. A., Brown, N., Nadeau, J., Smith, B., Page, D. L., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00001 · Cited by 464
Amar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., Jeunemaitre, X., Gimenez-Roqueplo, A.-P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0709 · Cited by 450
A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
Dahia, P. L. M., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M., Kung, A. L., Sanso, G., Powers, J. F., Tischler, A. S., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010008 · Cited by 443 · cited 2×
“Overall 267 (72%) 104 (28%) 371 (100%) Age (yr) 41 (6-83) 41 (5-77) 0.”
BackgroundNational Cancer Data Base report on malignant paragangliomas of the head and neck
Lee, J. H., Barich, F., Karnell, L. H., Robinson, R. A., Zhen, W. K., Gantz, B. J., Hoffman, H. T., & American College of Surgeons Commission on Cancer and the American Cancer Society (2002) · Cancer · doi:10.1002/cncr.10252 · Cited by 427
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma
Qin, Y., Yao, L., King, E. E., Buddavarapu, K., Lenci, R. E., Chocron, E. S., Lechleiter, J. D., Sass, M., Aronin, N., Schiavi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.533 · Cited by 379
Malignant pheochromocytoma: current status and initiatives for future progress
Eisenhofer, G., Bornstein, S. R., Brouwers, F. M., Cheung, N.-K. V., Dahia, P. L., de Krijger, R. R., Giordano, T. J., Greene, L. A., Goldstein, D. S., Lehnert, H., et al. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00829 · Cited by 338
Brouwers, F. M., Eisenhofer, G., Tao, J. J., Kant, J. A., Adams, K. T., Linehan, W. M., & Pacak, K. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0423 · Cited by 316
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Chrisoulidou, A., Kaltsas, G., Ilias, I., & Grossman, A. B. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0074 · Cited by 314
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma
Bayley, J.-P., Kunst, H. P., Cascon, A., Sampietro, M. L., Gaal, J., Korpershoek, E., Hinojar-Gutierrez, A., Timmers, H. J., Hoefsloot, L. H., Hermsen, M. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70007-3 · Cited by 276
Timmers, H. J. L. M., Kozupa, A., Eisenhofer, G., Raygada, M., Adams, K. T., Solis, D., Lenders, J. W. M., & Pacak, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2315 · Cited by 276
Bayley, J.-P., Devilee, P., & Taschner, P. E. (2005) · BMC Medical Genetics · doi:10.1186/1471-2350-6-39 · Cited by 184
Laparoscopic Adrenalectomy for Pheochromocytoma
Cheah, W. K., Clark, O. H., Horn, J., et al. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6669-x · Cited by 154
Pollard, P. J., El-Bahrawy, M. A., Poulsom, R., Elia, G., Killick, P., Kelly, G. P., Hunt, T., Jeffery, R. E., Seedhar, P., Barwell, J., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0920 · Cited by 154
Jiménez, C., Cote, G. J., Arnold, A., & Gagel, R. F. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2178 · Cited by 146
Self-citationOn the association of succinate dehydrogenase mutations with hereditary paraganglioma
Baysal, B. E. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2003.08.004 · Cited by 106
Niemann, S., Müller, U., Engelhardt, D., & Lohse, P. (2003) · Human Genetics · doi:10.1007/s00439-003-0938-0 · Cited by 82
Malignant Paragangliomas Associated with Mutations in the Succinate Dehydrogenase D Gene
Havekes, B., Corssmit, E. P. M., Jansen, J. C., van der Mey, A. G. L., Vriends, A. H. J. T., & Romijn, J. A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1993 · Cited by 81
Laparoscopic surgery for malignant adrenal tumors.
Zografos, G. N., Vasiliadis, G., Farfaras, A., Aggeli, C., & Digalakis, M. (2009) · PubMed Central · Cited by 64
Nomura, K., Kimura, H., Shimizu, S., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2697 · Cited by 64
Lodish, M. B., Adams, K. T., Huynh, T. T., Prodanov, T., Ling, A. L., Chen, C. C., Shusterman, S., Jiménez, C., Merino, M. J., Hughes, M. S., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0004 · Cited by 34
Laparoscopic adrenalectomy: Balancing the operative indications with the technical advances
Mazzaglia, P. J., & Vezeridis, M. P. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21565 · Cited by 31
New Advances in the Genetics of Pheochromocytoma and Paraganglioma Syndromes
Gimenez‐Roqueplo, A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.012 · Cited by 25
Waldmann, J., Langer, P., Habbe, N., Fendrich, V., Ramaswamy, A., Rothmund, Μ., Bartsch, D. K., & Slater, E. P. (2009) · Endocrine · doi:10.1007/s12020-009-9178-y · Cited by 21
Paraganglioma syndrome type 1 in a patient with Carney–Stratakis syndrome
Ayala‐Ramirez, M., Callender, G. G., Kupferman, M. E., Rich, T. A., Chuang, H. H., Trent, J. C., Perrier, N. D., Goodarzi, M., & Jiménez, C. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.250 · Cited by 20
Self-citationZabel, M., Dietel, M., Gębarowska, E., & Michael, R. (1999) · The Histochemical Journal · doi:10.1023/a:1003597416140 · Cited by 12
Cited by
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
Fishbein, L., Leshchiner, I., Walter, V., Danilova, L., Robertson, A. G., Johnson, A. R., Lichtenberg, T. M., Murray, B. A., Ghayee, H. K., Else, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.001 · Cited by 789
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas
Mete, O., Asa, S. L., Gill, A. J., Kimura, N., de Krijger, R. R., & Tischler, A. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09704-6 · Cited by 424
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Berruti, A., Baudin, E., Gelderblom, H., Haak, H. R., Porpiglia, F., Fassnacht, M., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds231 · Cited by 331
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years
Hamidi, O., Young, W. F., Iñiguez-Ariza, N. M., Kittah, N. E., Gruber, L., Bancos, C., Tamhane, S., & Bancos, I. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00992 · Cited by 316
Metadata
- Authors
- Ayala-Ramirez, M., Feng, L., Johnson, M. M., Ejaz, S., Habra, M. A., Rich, T., Busaidy, N., Cote, G. J., Perrier, N., Phan, A., Patel, S., Waguespack, S., & Jimenez, C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-03-01
- Volume
- 96
- Issue
- 3
- Pages
- 717-725
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2052953554
- Cited by
- 428
- References
- 36
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.